My #1 Income Strategy For 2025 (Safety, 14% Dividends On The Table)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2024
0mins
Source: NASDAQ.COM
Investment Strategy: Investing in closed-end funds (CEFs) can provide higher income streams and diversification opportunities compared to traditional index funds, especially by reallocating profits into underperforming sectors like healthcare.
Fund Comparison: While the abrdn Healthcare Investors Fund (HQH) offers high dividends, the BlackRock Health Sciences Trust (BME) may be a better long-term investment due to its stronger management and discount-management program, despite its lower yield.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BME?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BME
About BME
BlackRock Health Sciences Trust (the Trust) is a closed-end management investment company. The Trust investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, approximately 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. The Trust is focused on achieving its goal primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options. The Trust invests in a portfolio of sectors, which include biotechnology, health care equipment and supplies, life sciences tools and services, and pharmaceuticals. BlackRock Advisors, LLC acts as the manager of the Trust.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BlackRock Closed-End Funds Distribution Announcement
- Distribution Frequency Change: Certain BlackRock closed-end funds have announced a shift from monthly to quarterly distributions to enhance visibility on future payouts, thereby boosting investor confidence and optimizing liquidity.
- Distribution Amount Overview: For instance, the BlackRock Municipal 2030 Target Term Trust (BTT) has a monthly distribution of $0.046400, indicating stable cash flow that is expected to attract more investors seeking reliable income.
- Managed Distribution Plan: The BlackRock Capital Allocation Term Trust (BCAT) and BlackRock ESG Capital Allocation Term Trust (ECAT) have adopted a managed distribution plan to ensure a monthly distribution rate of 20% of each fund's 12-month rolling average net asset value, maintaining investor yield expectations.
- Tax Compliance Notices: All funds have sent Section 19 notices to shareholders to comply with the Investment Company Act of 1940, enhancing transparency and assisting investors in understanding the sources and tax characteristics of distributions.
See More
BlackRock Funds Announce 2026 Distribution Plans
- Distribution Amounts Announced: BlackRock's various funds announced distributions for February 27, 2026, with BCX distributing $0.0697 per share and BME distributing $0.2621 per share, indicating the company's ongoing cash flow and profitability.
- Managed Distribution Plan: All funds have adopted a managed distribution plan to ensure stable monthly distributions, with BCAT and ECAT's distributions based on 20% of their 12-month rolling average net asset value, reflecting the company's robust capital management strategy.
- Transparent Sources of Income: The sources of distributions for each fund include net income, short-term, and long-term capital gains, with BCX's distribution being 100% return of capital, showcasing its adaptability in the current market environment.
- Increased Investor Confidence: The distribution plans and transparent income sources of BlackRock funds are expected to enhance investor confidence, promote capital inflows, and further support the company's long-term growth strategy.
See More
Announcement of Distribution Dates and Amounts for Specific BlackRock Closed-End Funds
Distribution Dates Announced: Specific distribution dates for certain BlackRock closed-end funds have been announced.
Amounts Specified: The announcement includes details on the amounts to be distributed for these funds.
See More
BLACKROCK CLOSED-END FUNDS DISCLOSE ESTIMATED DISTRIBUTION SOURCES
BlackRock Closes End Funds: BlackRock has announced the closure of certain end funds, indicating a strategic shift in their investment approach.
Estimated Sources of Distributions: The announcement includes details on the estimated sources of distributions for the affected funds, providing transparency to investors.
See More
Medtronic Approaches Dividend King Status
- Dividend Growth Record: Medtronic has raised its dividend for 48 consecutive years, nearing Dividend King status, which reflects its strong business model and stable financial performance, likely attracting more long-term investors.
- Business Diversification: With a diversified portfolio across cardiovascular, neuroscience, and surgical sectors, Medtronic is set to maintain strong growth potential even after spinning off its diabetes business, ensuring competitiveness in the medical device industry.
- Innovation Drive: The introduction of the Hugo surgical robot exemplifies Medtronic's commitment to innovation in a fast-growing medical market, indicating that ongoing investments in technology will enhance future market share.
- Future Growth Expectations: Management projects a revenue growth of 5.5% for fiscal 2026, which is a solid target for a company with a market value of $120 billion, showcasing its potential to achieve growth during its transformation.
See More
Medtronic: The Investment Appeal of a Medical Device Giant
- Diversified Business Portfolio: Medtronic, as one of the world's largest medical device companies, operates across cardiovascular, neuroscience, and surgical sectors, and despite the upcoming spinoff of its diabetes business, it maintains strong growth potential, showcasing its competitive edge in the healthcare market.
- Innovation-Driven Growth: The Hugo surgical robot exemplifies Medtronic's innovative capabilities in a rapidly growing medical market, and with a long history of success, the company's ongoing investments at the technological forefront keep it ahead in the industry.
- Stable Dividend Record: With 48 consecutive years of dividend increases, Medtronic is nearing the status of a 'Dividend King', and this robust dividend growth record reflects its solid business model and execution during economic fluctuations, enhancing investor confidence.
- Future Growth Expectations: The company anticipates a revenue growth of 5.5% for fiscal 2026, and in the context of a $120 billion market value, this target indicates that Medtronic is beginning to see early benefits from its transformation, further solidifying its market position.
See More
BlackRock Closed-End Funds Distribution Announcement
- Distribution Frequency Change: Certain BlackRock closed-end funds have announced a shift from monthly to quarterly distributions to enhance visibility on future payouts, thereby boosting investor confidence and optimizing liquidity.
- Distribution Amount Overview: For instance, the BlackRock Municipal 2030 Target Term Trust (BTT) has a monthly distribution of $0.046400, indicating stable cash flow that is expected to attract more investors seeking reliable income.
- Managed Distribution Plan: The BlackRock Capital Allocation Term Trust (BCAT) and BlackRock ESG Capital Allocation Term Trust (ECAT) have adopted a managed distribution plan to ensure a monthly distribution rate of 20% of each fund's 12-month rolling average net asset value, maintaining investor yield expectations.
- Tax Compliance Notices: All funds have sent Section 19 notices to shareholders to comply with the Investment Company Act of 1940, enhancing transparency and assisting investors in understanding the sources and tax characteristics of distributions.
See More
BlackRock Funds Announce 2026 Distribution Plans
- Distribution Amounts Announced: BlackRock's various funds announced distributions for February 27, 2026, with BCX distributing $0.0697 per share and BME distributing $0.2621 per share, indicating the company's ongoing cash flow and profitability.
- Managed Distribution Plan: All funds have adopted a managed distribution plan to ensure stable monthly distributions, with BCAT and ECAT's distributions based on 20% of their 12-month rolling average net asset value, reflecting the company's robust capital management strategy.
- Transparent Sources of Income: The sources of distributions for each fund include net income, short-term, and long-term capital gains, with BCX's distribution being 100% return of capital, showcasing its adaptability in the current market environment.
- Increased Investor Confidence: The distribution plans and transparent income sources of BlackRock funds are expected to enhance investor confidence, promote capital inflows, and further support the company's long-term growth strategy.
See More
Announcement of Distribution Dates and Amounts for Specific BlackRock Closed-End Funds
Distribution Dates Announced: Specific distribution dates for certain BlackRock closed-end funds have been announced.
Amounts Specified: The announcement includes details on the amounts to be distributed for these funds.
See More
BLACKROCK CLOSED-END FUNDS DISCLOSE ESTIMATED DISTRIBUTION SOURCES
BlackRock Closes End Funds: BlackRock has announced the closure of certain end funds, indicating a strategic shift in their investment approach.
Estimated Sources of Distributions: The announcement includes details on the estimated sources of distributions for the affected funds, providing transparency to investors.
See More
Medtronic Approaches Dividend King Status
- Dividend Growth Record: Medtronic has raised its dividend for 48 consecutive years, nearing Dividend King status, which reflects its strong business model and stable financial performance, likely attracting more long-term investors.
- Business Diversification: With a diversified portfolio across cardiovascular, neuroscience, and surgical sectors, Medtronic is set to maintain strong growth potential even after spinning off its diabetes business, ensuring competitiveness in the medical device industry.
- Innovation Drive: The introduction of the Hugo surgical robot exemplifies Medtronic's commitment to innovation in a fast-growing medical market, indicating that ongoing investments in technology will enhance future market share.
- Future Growth Expectations: Management projects a revenue growth of 5.5% for fiscal 2026, which is a solid target for a company with a market value of $120 billion, showcasing its potential to achieve growth during its transformation.
See More
Medtronic: The Investment Appeal of a Medical Device Giant
- Diversified Business Portfolio: Medtronic, as one of the world's largest medical device companies, operates across cardiovascular, neuroscience, and surgical sectors, and despite the upcoming spinoff of its diabetes business, it maintains strong growth potential, showcasing its competitive edge in the healthcare market.
- Innovation-Driven Growth: The Hugo surgical robot exemplifies Medtronic's innovative capabilities in a rapidly growing medical market, and with a long history of success, the company's ongoing investments at the technological forefront keep it ahead in the industry.
- Stable Dividend Record: With 48 consecutive years of dividend increases, Medtronic is nearing the status of a 'Dividend King', and this robust dividend growth record reflects its solid business model and execution during economic fluctuations, enhancing investor confidence.
- Future Growth Expectations: The company anticipates a revenue growth of 5.5% for fiscal 2026, and in the context of a $120 billion market value, this target indicates that Medtronic is beginning to see early benefits from its transformation, further solidifying its market position.
See More
